



Splitting sisters to treat cancer


Petra van der Lelij, Nikola Winter, Tom Ellis



Bladder cancer


- 3.4 million sufferers worldwide
- 430,000 new cases every year
- 196,000 deaths
- 6th most common cancer in the US

We lack specific treatments




- Current drugs disrupt cell division generally


We lack specific treatments




- Current drugs disrupt cell division generally
- Market expected to double by 2025




Healthy cells




Cancer cells






Healthy cells




Cancer cells





Drug






Healthy cells



Cancer cells




Drug






There are two ways to achieve this



- Mechanism works
- We know the structure of the protein




There are two ways to achieve this



- Mechanism works
- We know the structure of the protein
- We have 5 potential candidate molecules
- **Identify and develop the optimal compound to do this**

No other drugs target bladder cancer





Team

- Dr. Petra van der Lelij
 - 15 years experience in cancer biology
 - Lead the research team
- Dr. Mark Petronczki
 - Expert scientific advisor
- Dr Tom Ellis
 - Head of sales
- Dr Nikola Winter
 - Venture-capital investor



Why is this so promising?

- Personalised treatment to reduce side-effects
- Meaningful difference to patient's lives
- Market set to double in 6 years
- Predictable efficiency